Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Report 2025

The sphingosine 1 phosphate receptor (S1PR) modulator drugs market size has grown strongly in recent years. It will grow from $2.44 billion in 2024 to $2.57 billion in 2025 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to the rising prevalence of autoimmune diseases, increased investment in autoimmune drug development, expansion of indications, growing awareness of autoimmune disease management, and rising healthcare expenditure.

The sphingosine 1 phosphate receptor (S1PR) modulator drugs market size is expected to see strong growth in the next few years. It will grow to $3.2 billion in 2029 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to growing demand for oral therapies over injectables, increasing prevalence of autoimmune diseases, rising healthcare expenditure globally, growth in awareness and diagnosis of conditions like multiple sclerosis, and rising geriatric population prone to autoimmune diseases. Major trends in the forecast period include advancements in receptor selectivity, regulatory approvals for new indications, integration of real-world evidence (RWE), technological advancements in drug delivery, a shift toward oral therapies, strategic collaborations, and acquisitions.

The forecast of 5.6% growth over the next five years reflects a modest reduction of 0.4% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could burden U.S. neurology clinics by driving up prices of fingolimod derivatives and MS relapse prevention therapies manufactured in Switzerland and Japan. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing prevalence of autoimmune diseases is expected to drive the expansion of the sphingosine 1-phosphate receptor (S1PR) modulator drugs market. Autoimmune diseases occur when the immune system mistakenly attacks the body's healthy cells, leading to inflammation and tissue damage. Factors such as genetics, environmental triggers, lifestyle changes, and improved diagnostic capabilities contribute to the growing incidence of these conditions. S1PR modulator drugs help regulate immune cell migration, reducing inflammation in autoimmune diseases such as multiple sclerosis and ulcerative colitis. For example, in May 2024, data published by the National Center for Health Statistics (NCHS), a US-based health statistics agency, indicated that the prevalence of current asthma among adults aged 18 and over in the United States increased from 8.4% in 2021 to 8.7% in 2022. Additionally, the incidence of asthma episodes within the past 12 months for adults in the same age group rose from 3.3% in 2021 to 3.7% in 2022. As a result, the rising prevalence of autoimmune diseases is fueling the growth of the S1PR modulator drugs market.

Leading companies in the S1PR modulator drugs market are emphasizing the development of innovative therapies, such as oral treatments, to improve patient compliance, enhance drug efficacy, and expand the therapeutic potential of these medications in managing autoimmune diseases. Oral therapy involves administering medications in pill or tablet form, providing a convenient and non-invasive treatment option for patients. For instance, in March 2022, Pfizer, a US-based pharmaceutical and biotechnology company, announced positive phase 3 trial results for etrasimod in ulcerative colitis patients. The drug met its primary and key secondary endpoints, demonstrating significant improvements in remission rates, endoscopic outcomes, and symptom relief. These results highlight etrasimod’s potential as a new treatment option for moderate-to-severe ulcerative colitis. Pfizer plans to advance regulatory submissions, reinforcing its immuno-inflammatory disease portfolio and commitment to innovative healthcare solutions.

In December 2023, Vanda Pharmaceuticals, a US-based pharmaceutical company, acquired the U.S. and Canadian rights to PONVORY from Actelion Pharmaceuticals Ltd. for an undisclosed amount. This acquisition strengthens Vanda’s portfolio by adding an innovative therapy for relapsing multiple sclerosis (MS), a condition with increasing prevalence and a significant unmet medical need. Actelion Pharmaceuticals Ltd., a Switzerland-based biopharmaceutical company, specializes in developing sphingosine 1-phosphate receptor (S1PR) modulator drugs for various diseases.

Major players in the sphingosine 1 phosphate receptor (s1pr) modulator drugs market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Bristol Myers Squibb Company, Novartis International AG, Biogen Inc., Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Ono Pharmaceutical Co. Ltd., Actelion Pharmaceuticals Ltd., KYORIN Pharmaceutical Co. Ltd., Vanda Pharmaceuticals Inc., Celgene Corporation, Ventyx Biosciences Inc., Idorsia Pharmaceuticals Ltd., Cayman Chemical Company, Juvisé Pharmaceuticals, Priothera Limited, and Arena Pharmaceuticals.

Asia-Pacific was the largest region in the sphingosine 1 phosphate receptor (S1PT) modulator drugs market in 2024. The regions covered in sphingosine 1 phosphate receptor (S1PR) modulator drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the sphingosine 1 phosphate receptor (S1PR) modulator drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The sphingosine 1 phosphate receptor (S1PR) modulator drugs market consists of sales of non-selective S1PR modulators, selective S1PR1 modulators, and next-generation and experimental S1PR modulators. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment - many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The sphingosine 1 phosphate receptor (S1PR) modulator drugs market research report is one of a series of new reports that provides sphingosine 1 phosphate receptor (S1PR) modulator drugs market statistics, including the sphingosine 1 phosphate receptor (S1PR) modulator drugs industry global market size, regional shares, competitors with the sphingosine 1 phosphate receptor (S1PR) modulator drugs market share, detailed sphingosine 1 phosphate receptor (S1PR) modulator drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the sphingosine 1 phosphate receptor (S1PR) modulator drugs industry. This sphingosine 1 phosphate receptor (S1PR) modulator drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Sphingosine 1 phosphate receptor (S1PR) modulator drugs are a class of therapeutic agents that specifically target sphingosine-1-phosphate (S1P) receptors, a family of G-protein-coupled receptors involved in essential cellular processes. These drugs regulate the activity of S1P receptors, which play a crucial role in immune cell trafficking, vascular function, and inflammation.

The primary types of sphingosine 1 phosphate receptor (S1PR) modulator drugs include fingolimod and ozanimod. Fingolimod is an oral medication used for treating multiple sclerosis (MS) by modulating the immune system to prevent nerve damage associated with the disease. These drugs are available in different routes of administration, including oral, injectable, and topical forms, and are used for treating multiple sclerosis, cardiovascular diseases, and transplant rejection. Their primary end-users include hospitals, rehabilitation centers, and retail pharmacies.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.